Rexahn Pharmaceuticals Cultura de la Empresa

Dr. Ely Benaim, M.D. has been the Chief Medical Officer of Rexahn Pharmaceuticals, Inc. since February 2015. In this role, Dr. Benaim responsible for leading Rexahn's clinical development programs and providing strategic and clinical guidance for Rexahn Pharmaceuticals. Dr. Benaim has more than 25 years of experience in healthcare including 15 years of clinical research experience in academia, government and pharmaceutical industry, as well as extensive experience in global regulatory affairs. Dr. Benaim was Senior Vice President of Regulatory Affairs & Chief Medical Officer of Berg Pharma. Prior to joining Berg Pharma, Dr. Benaim was Global Clinical Development Leader at Millennium Pharmaceuticals Inc. /Takeda Pharmaceuticals Company where he oversaw global clinical development of the Aurora A kinase inhibitor program. Prior to joining Takeda in 2011, Dr. Benaim served as Vice President of Clinical Affairs for Sangamo BioSciences where he lead the development of zinc-fingers transcription factors cellular therapies in the areas of Cancer, Diabetes, Neurology, Cardiovascular and HIV. Before Sangamo, Dr. Benaim served at Amgen as Global Clinical Lead for clinical development across several drug development programs. Prior to Amgen he was a Senior Director, Oncology Clinical Development at Salmedix, Inc. / Cephalon Inc. (now Teva Pharmaceuticals) where he led the development of TREANDA?? to a Phase 3 pivotal trial for lymphoma. From 1997 to 2004, he was Assistant Professor in the Department of Pediatrics at the University of Tennessee and an Assistant Member to the Department of Hematology/Oncology. As a member of the Transplantation and Gene Therapy program he published several manuscripts on the areas of stem cell transplantation, immunology and gene therapy. Dr. Benaim also has a passion for global pediatric cancer awareness and care and has been awarded for his contributions in Latin America and the United States. Dr. Benaim received his M.D. from the Universidad Central de Venezuela, Caracas and completed his pediatric residency training at the University of South Florida. He completed fellowships in pediatric oncology and bone marrow transplantation at St. Jude's Children's Research Hospital, in Memphis, Tennessee.

Dr. Tae Heum Jeong, also known as Ted, has been the Chief Financial Officer of Rexahn Pharmaceuticals, Inc. May 2005. Dr. Jeong serves as Senior Vice President of Rexahn Pharmaceuticals, Inc. He served as Chief Financial Officer of Rexahn, Corp from December 2002 to May 2005. He has extensive experience in the financial, investment and business aspects of bioscience businesses. From 1997 to November 2002, he served as a Senior Investment Manager of Hyundai Venture Investment Corporation. At Hyundai, he managed the biotech investment team and operated two specialized biotechnology funds. After joining Rexahn, his accomplishments include securing public market listings, mergers and successful fundraising efforts. He served as a Director at Rexahn Pharmaceuticals, Inc. from June 14, 2005 to June 18, 2012. He served as a Committee Member of the Industrial Development Fund of Korea's Ministry of Commerce, Industry and Energy from 2000 to 2002. Dr. Jeong holds a B.S. in chemistry and an M.S., specializing in bio-medicinal chemistry from Pohang University of Science and Technology (POSTECH). He holds an M.S. in Finance from Johns Hopkins University. Dr. Jeong holds a Doctor of Management from University of Maryland.

Ely Benaim serves as the Chief Medical Officer of Rexahn Pharmaceuticals. Ely started at Rexahn Pharmaceuticals in Feb of 2015. Ely currently resides in the Baltimore, Maryland Area.

Lisa Nolan serves as the Chief Business Officer of Rexahn Pharmaceuticals. Lisa started at Rexahn Pharmaceuticals in Jul of 2016. Lisa currently resides in the United States.